TN2009000400A1 - Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha - Google Patents

Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha

Info

Publication number: TN2009000400A1
Authority: TN; Tunisia
Prior art keywords: treating cancer; pyridopyrimidininone; inhibitors; methods; pi3k alpha
Prior art date: 2007-04-10

Application number

TNP2009000400A

Other languages

English (en)

Inventor

Peter Lamb

David Matthews

Original Assignee

Exelixis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-10

Filing date

2009-09-30

Publication date

2010-12-31

2009-09-30 Application filed by Exelixis Inc filed Critical Exelixis Inc

2010-12-31 Publication of TN2009000400A1 publication Critical patent/TN2009000400A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TNP2009000400A 2007-04-10 2009-09-30 Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha TN2009000400A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US92289907P	2007-04-10	2007-04-10
PCT/US2008/004573 WO2008124161A1 (fr)	2007-04-10	2008-04-09	Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone

Publications (1)

Publication Number	Publication Date
TN2009000400A1 true TN2009000400A1 (en)	2010-12-31

Family

ID=39627802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000400A TN2009000400A1 (en)	2007-04-10	2009-09-30	Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha

Country Status (31)

Country	Link
US (1)	US8513266B2 (fr)
EP (1)	EP2139484B9 (fr)
JP (3)	JP2010523670A (fr)
KR (1)	KR101626435B1 (fr)
CN (2)	CN102727498B (fr)
AU (1)	AU2008236562B2 (fr)
BR (1)	BRPI0810206A2 (fr)
CA (1)	CA2683641C (fr)
CO (1)	CO6251254A2 (fr)
CR (1)	CR11100A (fr)
DK (1)	DK2139484T3 (fr)
DO (1)	DOP2009000243A (fr)
EA (1)	EA020022B1 (fr)
EC (1)	ECSP099724A (fr)
ES (1)	ES2430614T3 (fr)
HN (1)	HN2009003002A (fr)
HR (1)	HRP20130688T1 (fr)
IL (1)	IL201284A (fr)
MA (1)	MA31358B1 (fr)
ME (1)	ME00936B (fr)
MX (1)	MX2009010930A (fr)
MY (1)	MY150697A (fr)
NZ (1)	NZ580110A (fr)
PL (1)	PL2139484T3 (fr)
PT (1)	PT2139484E (fr)
RS (1)	RS52939B (fr)
SI (1)	SI2139484T1 (fr)
TN (1)	TN2009000400A1 (fr)
UA (1)	UA100979C2 (fr)
WO (1)	WO2008124161A1 (fr)
ZA (1)	ZA200906764B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200726767A (en) *	2005-07-04	2007-07-16	Astrazeneca Ab	Chemical compounds 2
KR20140105621A (ko) *	2005-10-07	2014-09-01	엑셀리시스, 인코포레이티드	ＰＩ３Ｋα의 피리도피리미디논 억제제
CA2623768C (fr) *	2005-10-07	2016-04-12	Exelixis, Inc.	Derives de n-(3-amino-quinoxalin-2-yl) -sulfonamide et leur utilisation comme inhibiteurs de phosphatidylinositol 3-kinase
ATE539752T1 (de)	2006-08-16	2012-01-15	Exelixis Inc	Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
US8188113B2 (en) *	2006-09-14	2012-05-29	Deciphera Pharmaceuticals, Inc.	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SA08280783B1 (ar) *	2007-01-11	2011-04-24	استرازينيكا ايه بي	مشتقات بيريدوبيريميدين كمثبطات pde4
RS52939B (sr)	2007-04-10	2014-02-28	Exelixis Inc.	Postupci za lečenje kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
CA2684056A1 (fr) *	2007-04-11	2008-10-23	Exelixis, Inc.	Therapies combinees comprenant des inhibiteurs de quinoxaline de pi3k-alpha pour le traitement du cancer
JP5674661B2 (ja)	2008-08-20	2015-02-25	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
US8470834B2 (en)	2008-08-20	2013-06-25	Merck Sharp & Dohme Corp.	AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5619743B2 (ja) *	2008-08-20	2014-11-05	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	エテニル置換ピリジンおよびピリミジン誘導体およびウイルス感染の治療におけるそれらの使用
US8697694B2 (en)	2008-08-20	2014-04-15	Merck Sharp & Dohme Corp.	Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
UY33221A (es)	2010-02-09	2011-09-30	Univ California	MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
WO2012027536A1 (fr) *	2010-08-26	2012-03-01	Bristol-Myers Squibb Company	Combinaison d'anticorps anti-ctla4 avec des inhibiteurs de braf pour le traitement synergique de maladies prolifératives
CA2812089C (fr)	2010-09-14	2020-02-18	Exelixis Inc.	Inhibiteurs de pi3k-delta et leurs procedes d'utilisation et fabrication
WO2012065019A2 (fr)	2010-11-12	2012-05-18	Exelixis, Inc.	Inhibiteurs pyridopyrimidinone de p13k alpha
US9441013B2 (en) *	2011-05-17	2016-09-13	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Melanocortin 1 receptor ligands and methods of use
TW201306842A (zh) *	2011-06-15	2013-02-16	Exelixis Inc	使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
JP2014529298A (ja) *	2011-07-28	2014-11-06	ジェネンテック，インコーポレイテッド	Ｐｉｋ３ｃａｈ１０４７ｒノックイン非ヒト動物乳癌モデル
WO2013056067A1 (fr) *	2011-10-13	2013-04-18	Exelixis, Inc.	Composés pour une utilisation dans le traitement de carcinome des cellules basales
HK1201480A1 (en)	2011-11-01	2015-09-04	Exelixis, Inc.	N-(3-{[(3-{[2-chloro-5-(methoxy)phenyl]amino}quinoxalin-2-yl)amino]sulfonyl}phenyl)-2-methylalaninamide as phosphatidylinositol 3-kinase inhibitor for the treatment of lymphoproliferative malignancies
CN104204804B (zh) *	2011-11-11	2016-09-28	因特利凯有限责任公司	激酶抑制剂的组合及其用途
WO2013101964A1 (fr) *	2011-12-27	2013-07-04	Kadmon Corporation, Llc	Procédés de traitement d'un cancer du sein ne répondant pas au trastuzumab
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
BR112014032346A2 (pt)	2012-06-26	2017-06-27	Del Mar Pharmaceuticals	métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
US8980259B2 (en) *	2012-07-20	2015-03-17	Novartis Ag	Combination therapy
DK2882440T3 (da)	2012-08-07	2019-05-06	Novartis Ag	Farmaceutiske kombinationer, der omfatter en b-raf-inhibitor, en egfr-inhibitor og eventuelt en pi3k-alfa-inhibitor
CN105492011A (zh)	2013-04-08	2016-04-13	丹尼斯·M·布朗	不理想给药化学化合物的治疗增效
US9950194B2 (en)	2014-09-09	2018-04-24	Mevion Medical Systems, Inc.	Patient positioning system
US11883404B2 (en)	2016-03-04	2024-01-30	Taiho Pharmaceuticals Co., Ltd.	Preparation and composition for treatment of malignant tumors
WO2017150725A1 (fr)	2016-03-04	2017-09-08	大鵬薬品工業株式会社	Préparation et composition de traitement de tumeurs malignes
AU2017311645B2 (en) *	2016-08-15	2021-05-27	Pfizer Inc.	Pyridopyrimdinone CDK2/4/6 inhibitors
JP7027699B2 (ja) *	2017-05-09	2022-03-02	住友ゴム工業株式会社	タイヤトレッドおよびタイヤ
JP7523351B2 (ja)	2018-01-31	2024-07-26	デシフェラ・ファーマシューティカルズ，エルエルシー	肥満細胞症の治療のための併用療法
SG11202007198WA (en)	2018-01-31	2020-08-28	Deciphera Pharmaceuticals Llc	Combination therapy for the treatment of gastrointestinal stromal tumors
EP4470621A3 (fr)	2018-03-19	2025-05-07	Taiho Pharmaceutical Co., Ltd.	Composition pharmaceutique comprenant un monoester d'acide gras de saccharose
EP4013412A1 (fr)	2019-08-12	2022-06-22	Deciphera Pharmaceuticals, LLC	Ripretinib pour le traitement de tumeurs stromales gastro-intestinales
TWI878335B (zh)	2019-08-12	2025-04-01	美商迪賽孚爾製藥有限公司	治療胃腸道基質瘤方法
EP4073055A4 (fr) *	2019-12-10	2024-02-28	The Trustees of Indiana University	Inhibiteurs de l'interaction protéine a de réplication (rpa)-adn
IL293866A (en)	2019-12-30	2022-08-01	Deciphera Pharmaceuticals Llc	Compositions of amorphous kinase inhibitors and methods of using them
LT4084779T (lt)	2019-12-30	2024-11-11	Deciphera Pharmaceuticals, Llc	1-(4-brom-5-(1-etil-7-(metilamino)-2-okso-1,2-dihidro-1,6-naftiridin-3-il) -2- fluorfenil)-3-fenilkarbamido kompozicijos
KR102195221B1 (ko)	2019-12-31	2020-12-24	서울대학교산학협력단	포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물
CN111358952B (zh) *	2020-04-15	2022-03-15	中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所）	一种抗肿瘤药物组合物及其制剂和应用
CA3238551A1 (fr) *	2021-11-18	2023-05-25	Steven FRUCHTMAN	Methodes et compositions pour traitement du cancer
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7019002B2 (en) *	2001-12-11	2006-03-28	Pharmacia & Upjohn, S.P.A.	Pyridopyrimidinones derivatives as telomerase inhibitors
EP2280003B1 (fr) *	2002-07-15	2014-04-02	Symphony Evolution, Inc.	Procédé pour la préparation de modulateurs de kinases de type récepteur
CA2555724A1 (fr)	2004-02-18	2005-09-09	Warner-Lambert Company Llc	2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
ES2292130T3 (es) *	2004-05-04	2008-03-01	Warner-Lambert Company Llc	Pirido(2,3-d)pirimidin-7-onas pirrolil-sustituidas y derivados de las mismas como agentes terapeuticos.
TW200710406A (en) *	2005-07-06	2007-03-16	Sbc Corp	Leakage current detection apparatus and leakage current detection method
CA2623768C (fr)	2005-10-07	2016-04-12	Exelixis, Inc.	Derives de n-(3-amino-quinoxalin-2-yl) -sulfonamide et leur utilisation comme inhibiteurs de phosphatidylinositol 3-kinase
US8247408B2 (en) *	2005-10-07	2012-08-21	Exelixis, Inc.	Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
KR20140105621A (ko) *	2005-10-07	2014-09-01	엑셀리시스, 인코포레이티드	ＰＩ３Ｋα의 피리도피리미디논 억제제
ATE539752T1 (de)	2006-08-16	2012-01-15	Exelixis Inc	Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
CN101573358B (zh) *	2006-09-15	2012-05-30	辉瑞产品公司	吡啶并(2,3-d)嘧啶酮化合物及其作为pi3抑制剂的用途
RS52939B (sr)	2007-04-10	2014-02-28	Exelixis Inc.	Postupci za lečenje kancera upotrebom piridopirimidinonskih inhibitora pi3k alfa
CA2684056A1 (fr)	2007-04-11	2008-10-23	Exelixis, Inc.	Therapies combinees comprenant des inhibiteurs de quinoxaline de pi3k-alpha pour le traitement du cancer
CA2683784A1 (fr)	2007-04-11	2008-10-23	Exelixis, Inc.	Composes pyrido [2, 3-d] pyrimidin-7-one utilises en tant qu'inhibiteurs de pi3k-alpha pour le traitement du cancer
BRPI0810175A2 (pt)	2007-04-11	2014-12-30	Exelixis Inc	Inibidores pirididopirinidinona de p13k alfa
WO2010039740A1 (fr)	2008-09-30	2010-04-08	Exelixis, Inc.	Inhibiteurs de pyridopyrimidinone de la pi3 kinase α et de la mtor

2008
- 2008-04-09 RS RS20130384A patent/RS52939B/sr unknown
- 2008-04-09 EP EP08742677.1A patent/EP2139484B9/fr active Active
- 2008-04-09 US US12/595,219 patent/US8513266B2/en not_active Expired - Fee Related
- 2008-04-09 WO PCT/US2008/004573 patent/WO2008124161A1/fr not_active Ceased
- 2008-04-09 BR BRPI0810206-6A2A patent/BRPI0810206A2/pt not_active IP Right Cessation
- 2008-04-09 MY MYPI20094214 patent/MY150697A/en unknown
- 2008-04-09 EA EA200970932A patent/EA020022B1/ru not_active IP Right Cessation
- 2008-04-09 JP JP2010503045A patent/JP2010523670A/ja active Pending
- 2008-04-09 CN CN201210032620.4A patent/CN102727498B/zh not_active Expired - Fee Related
- 2008-04-09 CA CA2683641A patent/CA2683641C/fr not_active Expired - Fee Related
- 2008-04-09 UA UAA200911419A patent/UA100979C2/ru unknown
- 2008-04-09 SI SI200831004T patent/SI2139484T1/sl unknown
- 2008-04-09 NZ NZ580110A patent/NZ580110A/en not_active IP Right Cessation
- 2008-04-09 KR KR1020097023351A patent/KR101626435B1/ko not_active Expired - Fee Related
- 2008-04-09 PT PT87426771T patent/PT2139484E/pt unknown
- 2008-04-09 DK DK08742677.1T patent/DK2139484T3/da active
- 2008-04-09 PL PL08742677T patent/PL2139484T3/pl unknown
- 2008-04-09 AU AU2008236562A patent/AU2008236562B2/en not_active Ceased
- 2008-04-09 HR HRP20130688AT patent/HRP20130688T1/hr unknown
- 2008-04-09 ES ES08742677T patent/ES2430614T3/es active Active
- 2008-04-09 MX MX2009010930A patent/MX2009010930A/es active IP Right Grant
- 2008-04-09 ME MEP-2009-303A patent/ME00936B/fr unknown
- 2008-04-09 CN CN200880018725A patent/CN101715345A/zh active Pending
2009
- 2009-09-29 ZA ZA200906764A patent/ZA200906764B/xx unknown
- 2009-09-30 TN TNP2009000400A patent/TN2009000400A1/fr unknown
- 2009-10-01 IL IL201284A patent/IL201284A/en active IP Right Grant
- 2009-10-09 HN HN2009003002A patent/HN2009003002A/es unknown
- 2009-10-09 DO DO2009000243A patent/DOP2009000243A/es unknown
- 2009-11-02 MA MA32318A patent/MA31358B1/fr unknown
- 2009-11-09 EC EC2009009724A patent/ECSP099724A/es unknown
- 2009-11-09 CR CR11100A patent/CR11100A/es unknown
- 2009-11-09 CO CO09126924A patent/CO6251254A2/es not_active Application Discontinuation
2013
- 2013-09-19 JP JP2013194611A patent/JP2014034576A/ja active Pending
2014
- 2014-03-24 JP JP2014059561A patent/JP2014139217A/ja active Pending

Also Published As

Publication number	Publication date
US20100209420A1 (en)	2010-08-19
KR20100016354A (ko)	2010-02-12
IL201284A (en)	2016-06-30
HRP20130688T1 (en)	2013-09-30
EP2139484A1 (fr)	2010-01-06
AU2008236562B2 (en)	2013-11-07
ME00936B (fr)	2012-06-20
CN102727498B (zh)	2016-08-03
MX2009010930A (es)	2010-01-20
JP2014139217A (ja)	2014-07-31
ECSP099724A (es)	2010-03-31
DOP2009000243A (es)	2010-10-31
IL201284A0 (en)	2010-05-31
KR101626435B1 (ko)	2016-06-01
US8513266B2 (en)	2013-08-20
ES2430614T3 (es)	2013-11-21
DK2139484T3 (da)	2013-10-21
JP2014034576A (ja)	2014-02-24
CR11100A (es)	2010-01-19
UA100979C2 (ru)	2013-02-25
JP2010523670A (ja)	2010-07-15
AU2008236562A1 (en)	2008-10-16
EP2139484B9 (fr)	2014-06-11
CA2683641A1 (fr)	2008-10-16
BRPI0810206A2 (pt)	2014-10-21
EP2139484B8 (fr)	2013-08-21
MA31358B1 (fr)	2010-05-03
SI2139484T1 (sl)	2013-10-30
ZA200906764B (en)	2010-08-25
CN102727498A (zh)	2012-10-17
CN101715345A (zh)	2010-05-26
PL2139484T3 (pl)	2013-12-31
NZ580110A (en)	2012-06-29
EA200970932A1 (ru)	2010-04-30
EP2139484B1 (fr)	2013-07-17
HN2009003002A (es)	2014-03-24
CA2683641C (fr)	2016-08-16
MY150697A (en)	2014-02-28
EA020022B1 (ru)	2014-08-29
HK1139863A1 (en)	2010-09-30
RS52939B (sr)	2014-02-28
PT2139484E (pt)	2013-10-31
WO2008124161A1 (fr)	2008-10-16
CO6251254A2 (es)	2011-02-21

Publication	Publication Date	Title
TN2009000400A1 (en)	2010-12-31	Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
UA98141C2 (ru)	2012-04-25	Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
TR201900306T4 (tr)	2019-02-21	Mek inhibitörlerini kullanma yöntemleri.
TW200738725A (en)	2007-10-16	Unsaturated mTOR inhibitors
MX2009009786A (es)	2009-09-24	Inhibidores de la via de hedgehog.
TN2012000622A1 (en)	2014-04-01	Combinations of kinase inhibitors for the treatment of cancer
MY146111A (en)	2012-06-29	Acylaminopyrazoles as fgfr inhibitors
JO2886B1 (en)	2015-03-15	Useful compounds in the inhibition of CHK1
TW200740776A (en)	2007-11-01	N-phenylbenzotriazolyl c-kit inhibitors
NZ595572A (en)	2013-07-26	Inhibitors of pi3 kinase and / or mtor
MX2010010300A (es)	2010-10-26	Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
MY148688A (en)	2013-05-31	2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
TN2013000237A1 (en)	2014-11-10	Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor
MX2008011633A (es)	2008-12-16	Aminoquinolonas como inhibidores de gsk-3.
MX2010002667A (es)	2010-04-01	Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
MX2010004967A (es)	2010-07-30	Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.
UA96304C2 (en)	2011-10-25	2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
UA96969C2 (en)	2011-12-26	Acylaminopyrazoles as fgfr inhibitors
JO3145B1 (ar)	2017-09-20	مركبات مفيدة لتثبيط chk1
IN2012DN02816A (fr)	2015-07-24
WO2007136615A3 (fr)	2008-07-24	Thérapie anticancéreuse combinée
UA99612C2 (en)	2012-09-10	Inhibitors of the hedgehog pathway
CY1114609T1 (el)	2016-10-05	Μεθοδοι θεραπειας καρκινου χρησιμοποιωντας αναστολεις p13k αλφα με βαση πυριδοπυριμιδινονη